Latest news with #CleanCap
Business Wire
3 days ago
- Business
- Business Wire
TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology
SAN DIEGO--(BUSINESS WIRE)-- TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Under the agreement, Quantoom will have access to TriLink's CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production process and make life-saving therapeutics and vaccines more accessible to patients worldwide. "Strengthening global health against infectious diseases requires strong industry partnerships," said Becky Buzzeo, Chief Commercial Officer at Maravai. TriLink's CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when compared to legacy capping methods. Under this agreement, TriLink will supply its patented CleanCap technology for use in Quantoom's (sa)mRNA production platform, allowing customers to benefit from the industry's leading capping technology to develop their unique (sa)mRNA drugs using the Ntensify platform through clinical development phases. "Strengthening global health against infectious diseases requires strong industry partnerships," said Becky Buzzeo, Chief Commercial Officer at Maravai. "We're excited for the Quantoom production platform to incorporate TriLink's CleanCap reagents, a proven mRNA capping technology to deliver essential therapeutics and vaccines to nations with limited resources." Since its debut in 2017, TriLink's CleanCap capping technology has transformed the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. 'We are committed to making the RNA technology more accessible and scalable, and this partnership with TriLink is a key step toward that goal," said José Castillo, CEO of Quantoom Biosciences. "By integrating CleanCap analogs into our platform, we can further empower researchers and manufacturers to develop life-saving vaccines and therapeutics for communities in need." About TriLink BioTechnologies TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans. For more information about TriLink, visit About Maravai LifeSciences Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit About Quantoom Biosciences Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force TM toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode TM for sequence design and optimization, Ntensify ® for RNA production and Ncapsulate ® for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.
Yahoo
13-05-2025
- Business
- Yahoo
Maravai LifeSciences Holdings Inc (MRVI) Q1 2025 Earnings Call Highlights: Navigating Growth ...
Revenue: $47 million for Q1 2025. Nucleic Acid Production (NAP) Revenue: $29 million in Q1 2025. Biologic Safety Testing (BST) Revenue: $18 million in Q1 2025. GAAP Net Loss: $53 million for Q1 2025. Adjusted EBITDA: Negative $11 million for Q1 2025. Basic and Diluted EPS: Loss of $0.21 per share for Q1 2025. Adjusted EPS: Loss of $0.08 per share for Q1 2025. Cash and Cash Equivalents: $285 million at the end of Q1 2025. Long-term Debt: $298 million at the end of Q1 2025. Cash Used in Operations: $9 million for Q1 2025. Capital Expenditures: $4 million for Q1 2025. Depreciation and Amortization: $13 million for Q1 2025. Interest Expense: $4 million for Q1 2025. Stock-based Compensation: $10 million for Q1 2025. Total Shares Outstanding: 255 million shares at the end of March 2025. Warning! GuruFocus has detected 3 Warning Signs with MRVI. Release Date: May 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) reported $47 million in revenue for Q1 2025, exceeding expectations and showing growth from the previous quarter. The Nucleic Acid Production (NAP) segment saw an increase in revenue to $29 million, indicating growth in their core business. The company launched new innovative technologies, such as the Poly(A+) line to enhance mRNA performance, which could expand the clinical applications of mRNA. Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) has successfully integrated recent acquisitions, enhancing their oligo product portfolio and enzyme capabilities. The company signed five additional CleanCap license and supply agreements, expanding their customer base and market reach. Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) reported a GAAP net loss of $53 million for Q1 2025, compared to a $23 million loss in the same quarter last year. Adjusted EBITDA was negative $11 million, reflecting challenges in achieving profitability. The company has not yet secured any guaranteed purchase orders for high volume CleanCap from top customers with commercially approved vaccines. There is ongoing uncertainty regarding tariffs and trade dynamics, which could impact future operations and costs. The Biologic Safety Testing (BST) segment's revenue from China, while strong in Q1, faces potential risks from geopolitical tensions and tariffs. Q: Trey, in your prepared remarks, you spoke to a mix of new trials and some that got mixed, which I think was basically a wash for the quarter. What does your intel tell you about the focus areas for the new trials and then conversely the ones that are being discontinued? Why are those going away? A: William Martin, CEO: The preclinical was relatively flat, but the clinical actually had additions. This may indicate a focus on later-stage projects due to funding conservatism. We see a shift from COVID and infectious disease vaccines to a broader range of mRNA-supported modalities. Clinical expansion is evident, while preclinical remains flat. Q: What do you see as the biggest driver of incremental demand over the next 12 to 18 months on the CleanCap and BST side? A: William Martin, CEO: We don't expect high volume CleanCap to be zero forever, but until firm commitments are made, we remain conservative. Clinical progression leads to larger purchase orders, and our new Flanders 2 service facility offers opportunities for significant strides in mRNA production. Q: Is there any opportunity for you to take share, given that 100% of your manufacturing is done in the US? A: William Martin, CEO: We see renewed interest due to our US-based manufacturing and supply chain. Our vertical integration story is compelling, and while mRNA is strong globally, we aim to maintain access to international markets. Q: What are you seeing from biopharma customers regarding uncertainty around drug prices and from academic and government sectors with potential NIH funding cuts? A: Becky Buzzeo, Chief Commercial Officer: It's a mixed environment. Some customers have secured long-term funding, while others delay decisions due to funding uncertainties. We've seen an increase in run-rate business at lower dollar amounts, indicating smaller experiments but continued work. Q: Do you have any government work, whether direct or indirect, that we should be mindful of? A: William Martin, CEO: We have no direct government work currently. Our BARDA program is closed, and we have no direct NIH support. Our academic exposure is small, but we hope to increase it over time. Q: Can you comment on the strength in BST revenue and whether there's any seasonality or pull-forward effect? A: Kevin Herde, CFO: Q1 is typically a high point due to manufacturing cycles. We had a strong quarter in China, which was the second-highest revenue from China in nine quarters. We expect a seasonal dip in subsequent quarters. Q: Do you expect any tailwinds from the push for reshoring in the pharma sector? A: William Martin, CEO: We are well-positioned with US-based RUO and GMP production capabilities. The foresight to invest in these capabilities during the pandemic is now beneficial in the current trade environment. Q: Can you provide an update on the Flanders facilities and visibility there? A: William Martin, CEO: The Flanders service facility offers high visibility and customer intimacy, allowing us to predict demand two to three quarters in advance. We have capacity to handle incoming demand, which influences our guidance cadence. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Maravai Lifesciences Reports First Quarter 2025 Financial Results
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; and Revenue for the full year 2025 is expected to be in the range of $185.0 million to $205.0 million, unchanged from previous guidance. "Our first quarter revenue exceeded our guidance range, and our base business, which excludes revenue from high-volume CleanCap® for commercial vaccine programs, grew more than $4 million compared to the fourth quarter of 2024, reflecting solid execution and momentum across the business," said Trey Martin, CEO, Maravai LifeSciences. 'Our team remains committed to our return-to-growth strategy amid a dynamic and shifting macroeconomic environment. We believe our customer focus, our differentiated technologies and GMP services supporting clients from discovery through commercialization give us the best position to continue navigating the evolving landscape and drive long-term value for Maravai.' Revenue for the First Quarter 2025 Three Months Ended March 31, (Dollars in 000's) 2025 2024 Year-over-Year % Change Nucleic Acid Production $ 28,750 $ 46,016 (37.5 )% Biologics Safety Testing 18,100 18,163 (0.3 )% Total Revenue $ 46,850 $ 64,179 (27.0 )% First Quarter 2025 Financial Results by Reporting Segment Revenue for the first quarter was $46.9 million, representing a 27.0% decrease over the same period in the prior year and was driven by the following: Nucleic Acid Production revenue was $28.8 million for the first quarter, representing a 37.5% decrease year-over-year. The revenue decrease was primarily driven by a lack of high-volume CleanCap orders for commercial phase vaccine programs and lower demand for research and discovery products. Biologics Safety Testing revenue was $18.1 million for the first quarter, or relatively flat year-over-year. Net loss and Adjusted EBITDA (non-GAAP) were $(52.9) million and $(10.5) million, respectively, for the first quarter of 2025, compared to net loss and Adjusted EBITDA (non-GAAP) of $(22.7) million and $7.8 million, respectively, for the first quarter of 2024. Revenue Guidance for Full Year 2025 Maravai's revenue guidance for the full year 2025 is based on expectations for its existing base business and does not include revenue, if any, from high-volume CleanCap orders for commercial phase vaccine programs, or potential new acquisitions, if any, or items that have not yet been identified or quantified. This guidance is also subject to a number of risks, uncertainties and other factors, including those identified in 'Forward-looking Statements' below. Revenue expectations for the full year 2025 remain in the range of $185.0 million to $205.0 million. Conference Call and Webcast Maravai's management will host a conference call today at 2:00 p.m. PT/ 5:00 p.m. ET to discuss its financial results for the first quarter of 2025 and its financial guidance for 2025. To participate in the conference call by telephone, approximately 10 minutes before the call, dial (800) 343-4849 or (203) 518-9848 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at LIFESCIENCES HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)(Unaudited) Three Months EndedMarch 31, 2025 2024 Revenue $ 46,850 $ 64,179 Operating expenses: Cost of revenue 39,125 38,335 Selling, general and administrative 39,564 40,885 Research and development 4,888 5,032 Goodwill impairment 12,435 — Restructuring — (1,212 ) Total operating expenses 96,012 83,040 Loss from operations (49,162 ) (18,861 ) Other income (expense): Interest expense (6,778 ) (10,864 ) Interest income 3,225 7,210 Other income 24 106 Loss before income taxes (52,691 ) (22,409 ) Income tax expense 162 271 Net loss (52,853 ) (22,680 ) Net loss attributable to non-controlling interests (22,908 ) (10,602 ) Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (29,945 ) $ (12,078 ) Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted $ (0.21 ) $ (0.09 ) Weighted average number of Class A common shares outstanding, basic and diluted 143,425 132,333 MARAVAI LIFESCIENCES HOLDINGS, INC. RECONCILIATION OF NON-GAAP FINANCIAL INFORMATION(in thousands, except per share amounts)(Unaudited) Net Loss to Adjusted EBITDA (non-GAAP) Three Months EndedMarch 31, 2025 2024 Net loss $ (52,853 ) $ (22,680 ) Add: Amortization 7,030 6,869 Depreciation 5,693 4,786 Interest expense 6,778 10,864 Interest income (3,225 ) (7,210 ) Income tax expense 162 271 EBITDA (36,415 ) (7,100 ) Acquisition integration costs (1) 767 2,498 Stock-based compensation (2) 10,403 12,057 Merger and acquisition related expenses (3) 1,178 30 Acquisition related tax adjustment (4) (71 ) (113 ) Goodwill impairment (5) 12,435 — Restructuring costs (6) — 19 Other (7) 1,154 404 Adjusted EBITDA (non-GAAP) $ (10,549 ) $ 7,795 Net Loss attributable to Maravai LifeSciences Holdings, Inc. to Adjusted Net Loss (non-GAAP) and Adjusted Fully Diluted Loss Per Share (non-GAAP) Three Months EndedMarch 31, 2025 2024 Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (29,945 ) $ (12,078 ) Net loss impact from pro forma conversion of Class B shares to Class A common shares (22,908 ) (10,602 ) Adjustment to the provision for income tax (8) 5,456 2,530 Tax-effected net loss (47,397 ) (20,150 ) Acquisition integration costs (1) 767 2,498 Stock-based compensation (2) 10,403 12,057 Merger and acquisition related expenses (3) 1,178 30 Acquisition related tax adjustment (4) (71 ) (113 ) Goodwill impairment (5) 12,435 — Restructuring costs (6) — 19 Other (7) 1,154 404 Tax impact of adjustments (9) 1,095 (465 ) Net cash tax benefit retained from historical exchanges (10) — 352 Adjusted net loss (non-GAAP) $ (20,436 ) $ (5,368 ) Diluted weighted average shares of Class A common stock outstanding 255,457 252,025 Adjusted net loss (non-GAAP) $ (20,436 ) $ (5,368 ) Adjusted fully diluted loss per share (non-GAAP) $ (0.08 ) $ (0.02 ) ____________________Explanatory Notes to Reconciliations (1) Refers to incremental costs incurred to execute and integrate completed acquisitions, including retention payments related to integration that were negotiated specifically at the time of the Company's acquisition of MyChem, LLC ('MyChem') and Alphazyme, LLC ('Alphazyme'), which were completed in January 2022 and January 2023, respectively. These retention payments arise from the Company's agreements executed in connection with the acquisitions of MyChem and Alphazyme and provide incremental financial incentives, over and above recurring compensation, to ensure the employees of these companies remain present and participate in integration of the acquired businesses during the integration and knowledge transfer periods. The Company agreed to pay certain employees of Alphazyme retention payments totaling $9.3 million as of various dates but primarily through December 31, 2025, as long as these individuals continue to be employed by the Company. The Company agreed to pay the sellers of MyChem retention payments totaling $20.0 million as of the second anniversary of the closing of the acquisition date as long as two senior employees (who were also the sellers of MyChem) continue to be employed by TriLink. The Company considers the payment of these retention payments as probable and is recognizing compensation expense related to these payments in the post-acquisition period ratably over the service period. Retention payment expenses were $0.7 million (Alphazyme) and $2.4 million (MyChem $1.8 million; Alphazyme $0.6 million) for the three months ended March 31, 2025 and 2024, respectively. Retention expenses for MyChem concluded in the first quarter of 2024, and following the payments in the first quarter of 2024, there are no further retention expenses payable for MyChem. The remaining retention accrual for Alphazyme is $2.3 million, expected to be accrued ratably each quarter through December 31, 2025, with payments expected to be made in the first quarter of 2026. There are no further cash-based retention payments planned, other than those disclosed above, for acquisitions completed as of March 31, 2025. (2) Refers to non-cash expense associated with stock-based compensation. (3) Refers to diligence, legal, accounting, tax and consulting fees incurred in connection with acquisitions that were pursued but not consummated. (4) Refers to non-cash income associated with adjustments to the indemnification asset recorded in connection with the acquisition of MyChem. (5) Refers to goodwill impairment recorded for our Nucleic Acid Production segment. (6) Refers to restructuring costs (benefit) associated with the Cost Realignment Plan, which was implemented in November 2023. For the three months ended March 31, 2024, stock-based compensation benefit of $1.2 million related to forfeited stock awards in connection with the restructuring is included on the stock-based compensation line item. (7) For the three months ended March 31, 2025, refers to severance payments, inventory step-up charges in connection with the acquisition of Alphazyme, and other non-recurring costs that are deemed to be outside of the ordinary course of business. For the three months ended March 31, 2024, refers to inventory step-up charges and certain other adjustments in connection with the acquisition of Alphazyme, and other non-recurring costs that are deemed to be outside of the ordinary course of business. (8) Represents additional corporate income taxes at an assumed effective tax rate of approximately 24% applied to additional net loss attributable to Maravai LifeSciences Holdings, Inc. from the assumed proforma exchange of all outstanding shares of Class B common stock for shares of Class A common stock. (9) Represents income tax impact of non-GAAP adjustments at an assumed effective tax rate of approximately 24% and the assumed proforma exchange of all outstanding shares of Class B common stock for shares of Class A common stock. (10) Represents income tax benefits due to the amortization of intangible assets and other tax attributes resulting from the tax basis step up associated with the purchase or exchange of Maravai Topco Holdings, LLC units and Class B common stock, net of payment obligations under the Tax Receivable Agreement. Non-GAAP Financial Information This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include: Adjusted EBITDA and Adjusted fully diluted Earnings Per Share (EPS). Maravai defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization, certain non-cash items and other adjustments that we do not consider representative of our ongoing operating performance including, as applicable: (i) incremental costs incurred to execute and integrate completed acquisitions, and associated retention payments; (ii) non-cash expenses related to share-based compensation; (iii) expenses incurred for acquisitions that were pursued but not consummated (including legal, accounting and professional consulting services); (iv) non-cash income associated with adjustments to the carrying value of the indemnification asset recorded in connection with completed acquisitions; (v) impairment charges; (vi) restructuring costs; (vii) severance payments; and (viii) inventory step-up charges in connection with completed acquisitions. Maravai defines Adjusted Net Loss as tax-effected earnings before the adjustments described above, and the tax effects of those adjustments. Maravai defines Adjusted fully diluted EPS as Adjusted Net Loss divided by the diluted weighted average number of shares of Class A common stock outstanding for the applicable period, which assumes the proforma exchange of all outstanding units of Maravai Topco Holdings, LLC (paired with shares of Class B common stock) for shares of Class A common stock. These non-GAAP measures are supplemental measures of operating performance that are not prepared in accordance with GAAP and do not represent, and should not be considered as, an alternative to net loss, as determined in accordance with GAAP. Management uses these non-GAAP measures to understand and evaluate Maravai's core operating performance and trends and to develop short-term and long-term operating plans. Management believes the measures facilitate comparison of Maravai's operating performance on a consistent basis between periods and, when viewed in combination with its results prepared in accordance with GAAP, help provide a broader picture of factors and trends affecting Maravai's results of operations. These non-GAAP financial measures have limitations as an analytical tool, and you should not consider them in isolation, or as a substitute for analysis of Maravai's results as reported under GAAP. Because of these limitations, they should not be considered as a replacement for net loss, as determined by GAAP, or as a measure of Maravai's profitability. Management compensates for these limitations by relying primarily on Maravai's GAAP results and using non-GAAP measures only for supplemental purposes. The non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit Forward-looking Statements This press release contains, and Maravai's officers and representatives may from time-to-time make, 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements regarding Maravai's financial guidance for 2025; Maravai's customer focus and differentiated technologies and services helping Maravai navigate an evolving market and drive long-term value creation; growth opportunities, including both organic and inorganic growth; Maravai's acquisition of the DNA and RNA business of Officinae Bio and the assets of Molecular Assemblies, Inc. and the expected benefits thereof; and future innovations, constitute forward-looking statements and are identified by words like 'believe,' 'expect,' 'see,' 'project,' 'may,' 'will,' 'should,' 'seek,' 'anticipate,' or 'could' and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of Maravai's business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of management's control. Maravai's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause Maravai's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: The level of Maravai's customers' spending on and demand for outsourced nucleic acid production and biologics safety testing products and services. Maravai's operating results are prone to significant fluctuation, which may make Maravai's future operating results difficult to predict and could cause Maravai's actual operating results to fall below expectations or any guidance Maravai may provide. Uncertainty regarding the extent and duration of Maravai's revenue associated with high-volume sales of CleanCap® for commercial phase vaccine programs and the dependency of such revenue, in important respects, on factors outside our control. The impact of shifts in U.S. and foreign trade policy, including the imposition of tariffs, trade restrictions and retaliatory actions, on demand for Maravai's products and services and Maravai's customers' ability to commit funds to purchase such products and services. Maravai's ability to attract, retain and motivate a highly skilled workforce, including qualified key personnel. Use of Maravai's products by customers in the production of vaccines and therapies, some of which represent relatively new and still-developing modes of treatment, and the impact of unforeseen adverse events, negative clinical outcomes, development of alternative therapies, or increased regulatory scrutiny of these modes of treatment and their financial cost on Maravai's customers' use of its products and services. Competition with life science, pharmaceutical and biotechnology companies who are substantially larger than Maravai and potentially capable of developing new approaches that could make Maravai's products, services and technology obsolete. The potential failure of Maravai's products and services to not perform as expected and the reliability of the technology on which Maravai's products and services are based. The risk that Maravai's products do not comply with required quality standards. Market acceptance of Maravai's life science reagents. Maravai's ability to efficiently manage its strategic acquisitions and organic growth opportunities. Natural disasters, geopolitical instability (including the ongoing military conflicts in Ukraine and the Middle East) and other catastrophic events. Risks related to Maravai's acquisitions, including whether Maravai achieves the anticipated benefits of acquisitions of businesses or technologies. Product liability lawsuits. Maravai's dependency on a limited number of customers for a high percentage of its revenue and Maravai's ability to maintain its current relationships with such customers. Maravai's reliance on a limited number of suppliers or, in some cases, sole suppliers, for some of Maravai's raw materials and the risk that Maravai may not be able to find replacements or immediately transition to alternative suppliers. The risk that Maravai's products become subject to more onerous regulation by the U.S. Food and Drug Administration or other regulatory agencies in the future. Maravai's ability to obtain, maintain and enforce sufficient intellectual property protection for Maravai's current or future products. The risk that a future cyber-attack or security breach cannot be prevented. Maravai's ability to protect the confidentiality of Maravai's proprietary information. The risk that one of Maravai's products may be alleged (or found) to infringe on the intellectual property rights of third parties. Compliance with Maravai's obligations under intellectual property license agreements. Maravai's or Maravai's licensors' failure to maintain the patents or patent applications in-licensed from a third party. Maravai's ability to adequately protect Maravai's intellectual property and proprietary rights throughout the world. Maravai's existing level of indebtedness and Maravai's ability to raise additional capital on favorable terms. Maravai's ability to generate sufficient cash flow to service all of Maravai's indebtedness. Maravai's potential failure to meet Maravai's debt service obligations. Restrictions on Maravai's current and future operations under the terms applicable to Maravai's credit agreement. Maravai's dependence, by virtue of Maravai's principal asset being its interest in Maravai Topco Holdings, LLC ('Topco LLC'), on distributions from Topco LLC to pay Maravai's taxes and expenses, including payments under a tax receivable agreement with the former owners of Topco LLC (the 'Tax Receivable Agreement' or 'TRA') together with various limitations and restrictions that impact Topco LLC's ability to make such distributions. The risk that conflicts of interest could arise between Maravai's shareholders and Maravai Life Sciences Holdings, LLC ('MLSH 1'), the only other member of Topco LLC, and impede business decisions that could benefit Maravai's shareholders. The substantial future cash payments Maravai may be required to make under the Tax Receivable Agreement to MLSH 1 and Maravai Life Sciences Holdings 2, LLC ('MLSH 2'), an entity through which certain of Maravai's former owners hold their interests in the Company and the negative effect of such payments. The fact that Maravai's organizational structure, including the TRA, confers certain benefits upon MLSH 1 and MLSH 2 that will not benefit Maravai's other common shareholders to the same extent as they will benefit MLSH 1 and MLSH 2. Maravai's ability to realize all or a portion of the tax benefits that are expected to result from the tax attributes covered by the Tax Receivable Agreement. The possibility that Maravai will receive distributions from Topco LLC significantly in excess of Maravai's tax liabilities and obligations to make to make payments under the Tax Receivable Agreement. Factors that could lead to future impairment of Maravai's goodwill and other amortizable intangible assets. Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of Maravai's income or other tax returns. Risks and uncertainty related to the restatement of Maravai's previously issued financial statements. Maravai's ability to remediate the material weaknesses in its internal control over financial reporting in a timely manner. Maravai's ability to design and maintain effective internal control over financial reporting in the future. The fact that investment entities affiliated with GTCR, LLC currently control a majority of the voting power of Maravai's outstanding common stock, and it may have interests that conflict with Maravai's or yours in the future. Risks related to Maravai's 'controlled company' status within the meaning of the corporate governance standards of NASDAQ. The potential anti-takeover effects of certain provisions in Maravai's corporate organizational documents. Potential sales of a significant portion of Maravai's outstanding shares of Class A common stock. Potential preferred stock issuances and the anti-takeover impacts of any such issuances. Such other factors as discussed throughout the sections entitled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in Maravai's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as well as other documents Maravai files with the Securities and Exchange Commission. Any forward-looking statements made in this release are based only on information currently available to management and speak only as of the date on which it is made. Maravai undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@ in to access your portfolio
Yahoo
22-03-2025
- Business
- Yahoo
Maravai Lifesciences price target lowered to $5 from $10 at Stifel
Stifel lowered the firm's price target on Maravai Lifesciences (MRVI) to $5 from $10 and keeps a Buy rating on the shares. The firm notes Q4 revenues came up $1M light of the Street, while EBITDA fell short by $7M. As for the guide, management's outlook is well below Street, but excludes all high volume CleanCap orders. Stifel believes the company is at point where the transition from COVID to non-COVID demand, the China uncertainty, and the opaqueness of key model area make for a low visibility situation. Maravai looks washed out at $2-$3, but remains a low-confidence Buy until greater clarity is gained and better growth materializes, the firm adds. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on MRVI: Questions or Comments about the article? Write to editor@ Maravai Lifesciences Projects 2025 Revenue and Expenses Buy Rating for Maravai Lifesciences Holdings: Strategic Financial Decisions and Growth Potential Amidst Challenges Maravai Lifesciences reports Q4 adjusted EPS (6c), consensus (4c) Maravai LifeSciences options imply 16.5% move in share price post-earnings May 05, 2025 Deadline: Contact Levi & Korsinsky LLP to Join Class Action Suit Against MRVI Sign in to access your portfolio
